The development of fluid biomarkers holds promise for enabling more effective drug development and establishing a more personalized medicine approach for Alzheimer’s disease (AD) diagnosis and treatment. Blood-based biomarkers exhibit high diagnostic accuracy in distinguishing AD from all other neurodegenerative diseases in patients with cognitive impairment and are soon to become the new gold standard in clinical practice. Longitudinal measurements of such biomarkers will also improve the detection of relevant disease-modifying effects of new drugs or lifestyle interventions.
